CRIS Current Research Information System

GELSOMINO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.703
NA - Nord America 1.914
EU - Europa 1.386
AF - Africa 161
SA - Sud America 145
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.313
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.881
CN - Cina 772
VN - Vietnam 759
SG - Singapore 617
IT - Italia 426
HK - Hong Kong 183
SE - Svezia 174
GB - Regno Unito 173
DE - Germania 150
BR - Brasile 111
IN - India 96
NL - Olanda 86
FR - Francia 85
KR - Corea 70
IE - Irlanda 56
FI - Finlandia 47
RU - Federazione Russa 45
TG - Togo 44
CI - Costa d'Avorio 40
JP - Giappone 39
JO - Giordania 28
CH - Svizzera 25
ZA - Sudafrica 25
BG - Bulgaria 21
UA - Ucraina 20
PH - Filippine 19
BE - Belgio 16
CA - Canada 15
MX - Messico 15
TH - Thailandia 15
BD - Bangladesh 14
ID - Indonesia 13
TR - Turchia 13
DZ - Algeria 11
EE - Estonia 11
EC - Ecuador 10
IQ - Iraq 10
PK - Pakistan 10
PL - Polonia 10
SC - Seychelles 10
AR - Argentina 8
AT - Austria 8
EG - Egitto 8
ES - Italia 8
NG - Nigeria 8
TW - Taiwan 8
VE - Venezuela 8
IL - Israele 5
MY - Malesia 5
HR - Croazia 4
IR - Iran 4
LB - Libano 4
TN - Tunisia 4
UZ - Uzbekistan 4
AU - Australia 3
KE - Kenya 3
LT - Lituania 3
OM - Oman 3
UY - Uruguay 3
AL - Albania 2
AZ - Azerbaigian 2
CL - Cile 2
CO - Colombia 2
CZ - Repubblica Ceca 2
KG - Kirghizistan 2
MA - Marocco 2
MK - Macedonia 2
MU - Mauritius 2
PA - Panama 2
PT - Portogallo 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BY - Bielorussia 1
CY - Cipro 1
DK - Danimarca 1
GA - Gabon 1
GR - Grecia 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MD - Moldavia 1
NO - Norvegia 1
NP - Nepal 1
PY - Paraguay 1
RS - Serbia 1
UG - Uganda 1
Totale 6.313
Salva come PNG Salva come JPEG
Città #
Singapore 449
Ashburn 276
Hong Kong 175
Shanghai 174
Ho Chi Minh City 150
Fairfield 142
Dong Ket 140
Hanoi 139
Southend 137
Hefei 133
Chandler 118
San Jose 106
Bologna 93
Houston 85
Santa Clara 82
Woodbridge 82
Beijing 78
Seoul 67
Seattle 62
Dublin 54
Princeton 53
Cambridge 51
Dallas 50
Wilmington 50
Lomé 44
Los Angeles 44
Ann Arbor 42
Abidjan 40
Council Bluffs 40
Milan 39
Boardman 37
Lauterbourg 35
Helsinki 34
Turin 30
Tokyo 27
Amman 26
Da Nang 24
Bern 21
Florence 21
Nanjing 20
Redmond 20
Redondo Beach 20
Sofia 18
Haiphong 17
New York 17
Frankfurt am Main 16
Jinan 16
San Diego 16
Brussels 15
Westminster 14
Buffalo 13
Bengaluru 12
Shenyang 12
Algiers 11
Biên Hòa 11
Falkenstein 11
Hải Dương 11
Johannesburg 11
São Paulo 11
Berlin 10
Des Moines 10
Bremen 9
Can Tho 9
Guangzhou 9
Lappeenranta 9
Medford 9
Tianjin 9
Visakhapatnam 9
Abeokuta 8
Bắc Giang 8
Chicago 8
Kyiv 8
Modena 8
The Dalles 8
Bangkok 7
Bühl 7
Hangzhou 7
Jakarta 7
Kerpen 7
Montreal 7
Nanchang 7
Ninh Bình 7
Orem 7
Redwood City 7
Shenzhen 7
Amsterdam 6
Boydton 6
Ha Long 6
Hyderabad 6
London 6
Mexico City 6
Padova 6
Phoenix 6
Quận Một 6
Saint Petersburg 6
Vienna 6
Warsaw 6
Xi'an 6
Atlanta 5
Campinas 5
Totale 4.038
Salva come PNG Salva come JPEG
Nome #
IFN-γ and CD38 in Hyperprogressive Cancer Development 427
A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event 328
Next-generation technologies in predictive molecular pathology of lung cancers 222
STK11 mutations correlate with poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status 221
PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD) 219
Arterial Embolization During Programmed Death-1 Inhibitor Treatment: An Unexpected Finding 200
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience 199
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial) 197
Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial 195
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players? 190
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors 184
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma 184
Nivolumab-induced cholangitic liver disease: A novel form of serious liver injury 183
Pembrolizumab in the treatment of metastatic non-small cell lung cancer: A review of current evidence 182
18F-FLT PET/CT in patients with advanced Non-Small Lung Cancer (NSCLC) treated with Nivolumab: preliminary results 182
Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer 177
Complete Recalcification Following Arterial Embolization of Massive Osteolytic Bone Metastasis From NSCLC 173
Immune-mediated cholangitis: is it always nivolumab’s fault? 169
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016 165
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC 165
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance 162
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies 161
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO) 159
Peripheral nervous system adverse events associated with immune checkpoint inhibitors 157
New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event 157
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab 151
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 150
Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancer 146
Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report 145
Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study 140
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System 132
The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers 130
Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) 125
Programmed death-1 inhibition and atherosclerosis: Can nivolumab vanish complicated atheromatous plaques? 90
null 75
EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature 74
Plasma genotyping for EGFR T790M in non-small cell lung cancer: Ready for clinical practice? 54
Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC 42
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis 29
Letter Re: Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations 20
Totale 6.461
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.494
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.494
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021252 0 0 0 0 0 0 0 0 0 32 27 193
2021/2022516 41 17 26 22 59 30 20 27 46 31 122 75
2022/2023678 49 110 52 71 34 47 26 44 126 17 64 38
2023/2024422 24 25 15 19 17 57 13 189 12 22 24 5
2024/20251.099 60 123 75 49 111 59 73 33 10 130 99 277
2025/20262.648 329 330 215 211 230 163 304 102 541 223 0 0
Totale 6.461